New patent for Nicox Ophthalmics drug ZERVIATE

Annual Drug Patent Expirations for ZERVIATE
Annual Drug Patent Expirations for ZERVIATE

Zerviate is a drug marketed by Nicox Ophthalmics
and is included in one NDA.

The generic ingredient in ZERVIATE is cetirizine hydrochloride. Additional details are available on the cetirizine hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Novartis Pharms drug PROMACTA

Annual Drug Patent Expirations for PROMACTA
Annual Drug Patent Expirations for PROMACTA

Promacta is a drug marketed by Novartis Pharms Corp
and is included in two NDAs. It is available from two suppliers. There are twenty-two patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and twenty-one patent family members in thirty countries.

The generic ingredient in PROMACTA is eltrombopag olamine. Two suppliers are listed for this compound. Additional details are available on the eltrombopag olamine profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent expiration for ROCHE drug TAMIFLU

Annual Drug Patent Expirations for TAMIFLU
Annual Drug Patent Expirations for TAMIFLU

Tamiflu is a drug marketed by Roche
and is included in two NDAs. It is available from five suppliers. There are two patents protecting this drug and three Paragraph IV challenges.

The generic ingredient in TAMIFLU is oseltamivir phosphate. Five suppliers are listed for this compound. Additional details are available on the oseltamivir phosphate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent expiration for Sunovion Pharms drug APTIOM

Annual Drug Patent Expirations for APTIOM
Annual Drug Patent Expirations for APTIOM

Aptiom is a drug marketed by Sunovion Pharms Inc
and is included in one NDA. It is available from one supplier. There are five patents protecting this drug.

This drug has sixty-nine patent family members in thirty countries.

The generic ingredient in APTIOM is eslicarbazepine acetate. One supplier is listed for this compound. Additional details are available on the eslicarbazepine acetate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New tentative approval for Watson Labs drug dienogest; estradiol valerate

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare
and is included in one NDA. There are four patents protecting this compound.

This ingredient has ninety-four patent family members in forty-three countries.

Three suppliers are listed for this compound. There is one tentative approval for this compound.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical drugs have the most drug patents in Greece?

This chart shows the drugs with the most patents in Greece.

Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

The companies with the greatest patent coverage in Greece are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New tentative approval for Watson Labs drug dienogest; estradiol valerate

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare
and is included in one NDA. There are four patents protecting this compound.

This ingredient has ninety-four patent family members in forty-three countries.

Three suppliers are listed for this compound. There is one tentative approval for this compound.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical companies have the most suppository dosed drugs?

This chart shows the pharmaceutical companies with the most suppository dosed drugs.

For a different perspective, see the most popular dosage types.

The companies with the most suppository dosed drugs are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com